Prediction of radiation pneumonitis using dose-volume histogram parameters with high attenuation in two types of cancer: A retrospective study
Open Access
- 28 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12), e0244143
- https://doi.org/10.1371/journal.pone.0244143
Abstract
The constraint values of dose-volume histogram (DVH) parameters for radiation pneumonitis (RP) prediction have not been uniform in previous studies. We compared the differences between conventional DVH parameters and DVH parameters with high attenuation volume (HAV) in CT imaging in both esophageal cancer and lung cancer patients to determine the most suitable DVH parameters in predicting RP onset. Seventy-seven and 72 patients who underwent radiation therapy for lung cancer and esophageal cancer, respectively, were retrospectively assessed. RP was valued according to the Common Terminology Criteria for Adverse Events. We quantified HAV with quantitative computed tomography analysis. We compared conventional DVH parameters and DVH parameters with HAV in both groups of patients. Then, the thresholds of DVH parameters that predicted symptomatic RP and the differences in threshold of DVH parameters between lung cancer and esophageal cancer patient groups were compared. The predictive performance of DVH parameters for symptomatic RP was compared using the area under the receiver operating characteristic curve. Mean lung dose, HAV30% (the proportion of the lung with HAV receiving ≥30 Gy), and HAV20% were the top three parameters in lung cancer, while HAV10%, HAV5%, and V10 (the percentage of lung volume receiving 10 Gy or more) were the top three in esophageal cancer. By comparing the differences in the threshold for parameters predicting RP between the two cancers, we saw that HAV30% retained the same value in both cancers. DVH parameters with HAV showed narrow differences in the threshold between the two cancer patient groups compared to conventional DVH parameters. DVH parameters with HAV may have higher commonality than conventional DVH parameters in both patient groups tested.Keywords
Funding Information
- Daiichi-Sankyo (A19-1287)
- Ono Pharmaceutical (ONOS20180618011)
- Pfizer Japan (54334665)
- Bayer Corporation (BASJ20180409030)
- Boehringer Ingelheim (RS2019A00769379)
- Astellas Pharma Global Development (RS2019A001313)
This publication has 24 references indexed in Scilit:
- Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline SummaryJournal of Oncology Practice, 2018
- Exclusion of emphysematous lung from dose-volume estimates of risk improves prediction of radiation pneumonitisRadiation Oncology, 2017
- Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trialAnnals of Oncology, 2017
- Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancerAnnals of Oncology, 2013
- Epidemiology, radiology, and genetics of nicotine dependence in COPDRespiratory Research, 2011
- 1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancerAnnals of Oncology, 2011
- European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung CancerJournal of Clinical Oncology, 2010
- Adding Ipsilateral V20 and V30 to Conventional Dosimetric Constraints Predicts Radiation Pneumonitis in Stage IIIA–B NSCLC Treated With Combined-Modality TherapyInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancerInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)International Journal of Radiation Oncology*Biology*Physics, 1999